Paloma Partners’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-5,151
Closed -$767K 2241
2021
Q4
$767K Buy
5,151
+3,181
+161% +$487K 0.01% 868
2021
Q3
$287K Buy
+1,970
New +$338K 0.01% 737
2021
Q1
Sell
-2,396
Closed -$339K 2366
2020
Q4
$339K Sell
2,396
-68,102
-97% -$9.88M 0.01% 1101
2020
Q3
$8.79M Buy
+70,498
New +$7.4M 0.22% 72
2019
Q4
Sell
-7,800
Closed -$393K 2518
2019
Q3
$393K Buy
+7,800
New +$432K 0.01% 1346

Other funds holding TXG

Paloma Partners's TXG Position: Q1 2022 in Review

Paloma Partners sold out of 10x Genomics (TXG) in Q1 2022, closing a stake of 5,151 shares — an estimated $767K sold.

Paloma Partners first reported a position in TXG in Q3 2019 and held it in 5 quarters. The position peaked at $8.79M in Q3 2020. 314 funds tracked by Wall St. Rank hold TXG as of Q1 2022.

  • Paloma Partners reported no remaining 10x Genomics position as of Q1 2022 after selling out during the quarter.
  • Paloma Partners sold 5,151 10x Genomics shares in Q1 2022, an estimated $767K.
  • Paloma Partners first reported a position in 10x Genomics in Q3 2019 and held it in 5 quarters.
  • Paloma Partners's 10x Genomics position peaked at $8.79M in Q3 2020.
  • 314 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2022.

Based on Paloma Partners's 13F filing for Q1 2022, filed 16 May 2022.